Claims for Patent: 8,202,517

Summary for Patent: 8,202,517

Title:	Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof
Abstract:	The invention relates to the discovery of novel soluble neutral active Hyaluronidase Glycoproteins (sHASEGP\'s), methods of manufacture, and their use to facilitate administration of other molecules or to alleviate glycosaminoglycan associated pathologies. Minimally active polypeptide domains of the soluble, neutral active sHASEGP domains are described that include asparagine-linked sugar moieties required for a functional neutral active hyaluronidase domain. Included are modified amino-terminal leader peptides that enhance secretion of sHASEGP. The invention further comprises sialated and pegylated forms of a recombinant sHASEGP to enhance stability and serum pharmacokinetics over naturally occurring slaughterhouse enzymes. Further described are suitable formulations of a substantially purified recombinant sHASEGP glycoprotein derived from a eukaryotic cell that generate the proper glycosylation required for its optimal activity.
Inventor(s):	Bookbinder; Louis H. (San Diego, CA), Kundu; Anirban (San Diego, CA), Frost; Gregory I. (Del Mar, CA)
Assignee:	Halozyme, Inc. (San Diego, CA)
Application Number:	12/378,969
Patent Claims:	1. A method for delivering a therapeutically effective drug or pharmaceutical agent to a subject, comprising: a) administering a hyaluronidase glycoprotein to a tissue in the subject in an amount sufficient to degrade glycosaminoglycans, wherein: the hyaluronidase glycoprotein consists of the sequence of amino acids set forth as amino acids 36-477, 36-478, 36-479, 36-480, 36-481, 36-482, or 36-483 of SEQ ID NO: 1, or contains amino acid substitutions in the sequence of amino acids set forth as amino acids 36-477, 36-478, 36-479, 36-480, 36-481, 36-482 or 36-483 of SEQ ID NO:1, whereby the amino-acid substituted hyaluronidase glycoprotein consists of a sequence of amino acids that has at least 95% amino acid sequence identity with the sequence of amino acids set forth as amino acids 36-477, 36-478, 36-479, 36-480, 36-481, 36-482 or 36-483 of SEQ ID NO:1; the glycoprotein is neutral active; and the glycoprotein contains at least one sugar moiety that is covalently attached to an asparagine (N) residue of the polypeptide; and b) administering a therapeutically effective amount of the drug or pharmaceutical agent to the subject. 2. The method of claim 1, wherein the drug or pharmaceutical agent is selected from among a small molecule and a protein. 3. The method of claim 1, wherein the drug or pharmaceutical agent is selected from among a chemotherapeutic agent, an analgesic agent, an anti-inflammatory agent, an antimicrobial agent, an amoebicidal agent, a trichomonocidal agent, an anti-Parkinson agent, an anti-malarial agent, an anticonvulsant agent, an anti-depressant agent, an anti-arthritic agent, an anti-fungal agent, an antihypertensive agent, an antipyretic agent, an anti-parasite agent, an antihistamine agent, an alpha-adrenergic agonist agent, an alpha blocker agent, an anesthetic agent, a bronchial dilator agent, a biocide agent, a bactericide agent, a bacteriostat agent, a beta adrenergic blocker agent, a calcium channel blocker agent, a cardiovascular drug agent, a contraceptive agent, a decongestant agent, a diuretic agent, a depressant agent, a diagnostic agent, an electrolyte agent, a hypnotic agent, a hormone agent, a hyperglycemic agent, a muscle relaxant agent, a muscle contractant agent, an ophthalmic agent, a parasympathomimetic agent, a sedative agent, a sympathomimetic agent, a tranquilizer agent, a viricide agent, a vitamin agent, a non-steroidal anti-inflammatory agent, an angiotensin converting enzyme inhibitor agent, a cytokine, an antibody, antibody fragment, an insulin and a sleep inducer. 4. The method of claim 3, wherein the chemotherapeutic agent is a toxin or a tumor necrosis factor. 5. The method of claim 3, wherein the anesthetic agent is lidocaine or bupivacaine. 6. The method of claim 1, wherein the drug or pharmaceutical agent is an insulin. 7. The method of claim 1, wherein the drug or pharmaceutical agent is a cytokine. 8. The method of claim 1, wherein the drug or pharmaceutical agent is an antibody or antibody fragment. 9. The method of claim 8, wherein the antibody or antibody fragment is a monoclonal antibody. 10. The method of claim 1, further comprising administering a hormonal agent. 11. The method of claim 10, wherein the hormonal agent is epinephrine. 12. The method of claim 10, wherein the hormonal agent is administered simultaneously or sequentially with the hyaluronidase glycoprotein. 13. The method of claim 1, wherein the hyaluronidase glycoprotein consists of a sequence of amino acids set forth as amino acids 36-477, 36-478, 36-479, 36-480, 36-481, 36-482, or 36-483 of SEQ ID NO:1. 14. The method of claim 1, wherein a composition comprising the hyaluronidase glycoprotein that consists of the sequence of amino acids set forth as amino acids 36-482 of SEQ ID NO:1 is administered. 15. The method of claim 1, wherein the hyaluronidase glycoprotein consists of the sequence of amino acids that contains amino acid substitutions in the sequence of amino acids set forth as amino acids 36-477, 36-478, 36-479, 36-480, 36-481, 36-482, or 36-483 of SEQ ID NO: 1, whereby the amino-acid substituted hyaluronidase glycoprotein consists of a sequence of amino acids that has at least 95% sequence identity with the sequence of amino acids set forth as amino acids36-477, 36-478, 36-479, 36-480, 36-481, 36-482, or 36-483 of SEQ ID NO: 1. 16. The method of claim 1, wherein the hyaluronidase glycoprotein is produced in and secreted from a mammalian cell by a method comprising: introducing an expression vector comprising a polynucleotide that consists of a sequence of nucleotides set forth as nucleotides 106-1446 of SEQ ID NO:6 or degenerates thereof or the sequence of nucleotides set forth in SEQ ID NO:48 or degenerates thereof inserted between flanking sequences in the vector into a mammalian cell; culturing the mammalian cell under conditions whereby the glycoprotein is expressed and secreted by the cell; and recovering a composition comprising the expressed and secreted hyaluronidase glycoprotein. 17. The method of claim 16, wherein the polynucleotide has the sequence of nucleotides set forth as SEQ ID NO:48. 18. The method of claim 16, wherein the mammalian cell is a CHO cell. 19. The method of claim 1, wherein the hyaluronidase glycoprotein is modified with a polymer. 20. The method of claim 19, wherein the polymer is a polyethylene glycol (PEG) or a dextran. 21. The method of claim 1, wherein the hyaluronidase glycoprotein is administered in an amount that is or is between 1 and 10,000 Units/ml. 22. The method of claim 1, wherein the hyaluronidase glycoprotein and molecule are provided in the same composition or as separate compositions. 23. The method of claim 1, wherein the hyaluronidase glycoprotein is administered prior to, simultaneously with or following administration of the molecule. 24. The method of claim 1, wherein the hyaluronidase glycoprotein is administered at a site that is different from the site of administration of the molecule. 25. The method of claim 1, wherein the hyaluronidase glycoprotein is administered at a site that is the same as the site of administration of the molecule. 26. The method of claim 1, wherein the hyaluronidase glycoprotein and/or drug or pharmaceutical agent is administered by parenteral administration. 27. The method of claim 26, wherein parenteral administration is selected from among subcutaneous, intravenous and intramuscular administration. 28. The method of claim 1, wherein the drug or pharmaceutical agent is a therapeutic agent.

Details for Patent 8,202,517

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Bausch & Lomb Incorporated	VITRASE	hyaluronidase	Injection	021640	May 05, 2004	8,202,517	2023-03-05
Bausch & Lomb Incorporated	VITRASE	hyaluronidase	Injection	021640	December 02, 2004	8,202,517	2023-03-05
Amphastar Pharmaceuticals, Inc.	AMPHADASE	hyaluronidase	Injection	021665	October 26, 2004	8,202,517	2023-03-05
Akorn, Inc.	HYDASE	hyaluronidase	Injection	021716	October 25, 2005	8,202,517	2023-03-05
Halozyme Therapeutics, Inc.	HYLENEX RECOMBINANT	hyaluronidase human	Injection	021859	December 02, 2005	8,202,517	2023-03-05

International Patent Family for US Patent 8,202,517

Country	Patent Number	Estimated Expiration
South Africa	200707898
South Africa	200507978
World Intellectual Property Organization (WIPO)	2006091871
World Intellectual Property Organization (WIPO)	2004078140
United States of America	9677062
United States of America	9677061
United States of America	9562223